These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 8062021)
1. Neuroblastoma in the first year of life: clinical and biologic factors influencing outcome. Grosfeld JL; Rescorla FJ; West KW; Goldman J Semin Pediatr Surg; 1993 Feb; 2(1):37-46. PubMed ID: 8062021 [TBL] [Abstract][Full Text] [Related]
2. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094 [TBL] [Abstract][Full Text] [Related]
3. MYCN protein expression as a predictor of neuroblastoma prognosis. Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553 [TBL] [Abstract][Full Text] [Related]
5. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152 [TBL] [Abstract][Full Text] [Related]
6. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100 [TBL] [Abstract][Full Text] [Related]
7. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154 [TBL] [Abstract][Full Text] [Related]
8. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis. Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488 [TBL] [Abstract][Full Text] [Related]
9. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847 [TBL] [Abstract][Full Text] [Related]
10. [Tumor cytogenetics and prognosis in neuroblastoma]. Christiansen H; Lampert F Monatsschr Kinderheilkd; 1989 Oct; 137(10):666-71. PubMed ID: 2586532 [TBL] [Abstract][Full Text] [Related]
12. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute. Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533 [TBL] [Abstract][Full Text] [Related]
14. [Neuroblastoma in children under than 1 year of age]. Castel Sánchez V; Melero Moreno C; García-Miguel García-Rosados P; Navajas Gutiérrez A; Ruiz Jiménez JI; Navarro Fos S; Garín Valle JC; Galbe Sada M An Esp Pediatr; 1997 Dec; 47(6):584-90. PubMed ID: 9575117 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912 [TBL] [Abstract][Full Text] [Related]
16. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493 [TBL] [Abstract][Full Text] [Related]
17. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery? Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341 [TBL] [Abstract][Full Text] [Related]
18. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Mora J; Cheung NK; Chen L; Qin J; Gerald W Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092 [TBL] [Abstract][Full Text] [Related]
19. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Woods WG; Lemieux B; Tuchman M Pediatrics; 1992 Jan; 89(1):114-8. PubMed ID: 1727993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]